MGLL and cancer: Monoacylglycerol lipase (MAGL) has emerged as a therapeutic target of high interest for treating a multitude of diseases related to inflammation, cancer, and neurodegeneration.[1, 2, 3, 4] MAGL is the key enzyme responsible for the hydrolysis of 2‐arachidonoylglycerol (2‐AG), the most abundant endocannabinoid (EC) ligand in the brain.[5] The endocannabinoid system (ECS) is a cell‐signaling network vital for the central nervous system (CNS).